Amsterdam, the Netherlands — November 18, 2025 — Leads & Copy —argenx SE (Euronext & Nasdaq: ARGX) has announced the results of its Extraordinary General Meeting of shareholders, which took place on November 18, 2025. The company’s remuneration policy, the only item up for a vote, was approved by a 95.67% majority. 91.1% of share capital was represented at the meeting.
The voting result and related documents are available on the argenx website.
argenx is a global immunology company focused on improving the lives of individuals with severe autoimmune diseases. Through its Immunology Innovation Program (IIP), argenx collaborates with academic researchers, aiming to develop antibody-based medicines. The company has commercialized the first approved neonatal Fc receptor (FcRn) blocker and is assessing its potential across various autoimmune diseases, while also developing earlier-stage experimental medicines within its therapeutic franchises.
For further information, please contact:
Media:
Ben Petok
Bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
Source: argenx SE
Source: argenx SE
